阿托伐他汀钙辅助治疗慢性充血性心力衰竭的临床疗效及药物安全性分析

The clinical efficacy and drug safety analysis of atorvastatin calcium in adjuvant treatment of chronic congestive heart failure

目的探讨阿托伐他汀钙辅助治疗慢性充血性心力衰竭的临床疗效及安全性。方法选择2012年4月至2015年4月于我院诊治的80例慢性充血性心力衰竭患者为研究对象,根据治疗方法的不同,将其分为对照组与治疗组,每组40例。两组患者均予以吸氧、β受体阻滞剂、利尿剂、洋地黄及硝酸酯类制剂等常规治疗,对照组仅行常规治疗,治疗组在行常规治疗基础上另加阿托伐他汀钙治疗,对比分析两组患者的临床治疗效果和不良反应发生情况。结果治疗组的治疗总有效率为87.5%,对照组为57.5%,治疗组明显高于对照组,差异具有统计学意义(P<0.05)。治疗组与对照组各有1例患者出现头昏、恶心等轻微症状,调整剂量后症状自行缓解,两组均未见严重不良反应。结论对慢性充血性心力衰竭患者在常规治疗的基础上辅以阿托伐他汀钙治疗,可获得较佳的疗效,且不会增加明显的不良反应,值得临床推广应用。

Objective To analyze the clinical efficacy and drug safety of atorvastatin calcium in adjuvant treatment of chronic congestive heart failure. Methods Eighty cases of patients with chronic congestive heart failure in our hospital from April 2012 to April 2015 were selected and divided into control group and treatment group according to the therapeutic method. All patients were given oxygen, β-blockers, diuretics, digitalis preparations, nitrates and other conventional treatment, the patients in the control group only accepted above methods, on the basis of this, the treatment group added atorvastatin calcium. The clinical effect and adverse reactions between the two groups were compared. Results The total effective rate of the treatment group was 87.5%, which was significantly higher than 57.5% of the control group （P〈0.05）. There was 1 case of patient with dizziness, nausea and other mild symptoms in each group, the symptoms relieved after dose adjustment, both of the two groups had no serious adverse reactions. Conclusion Atorvastatin calcium on the basis of eonvertional treatment in adjuvant treatment of chronic congestive heart failure has a significant efficacy, without obviously increasing the adverse reactions, and is worthy of clinical application